Stenocare A/S

STENO

DK0061078425

Pharmaceuticals

Delayed Nasdaq Copenhagen Other stock markets 04:34:04 2024-04-29 am EDT			5-day change	1st Jan Change
4.99 ^DKK	0.00%		-7.93%	+96.46%

Apr. 18	Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in Denmark	CI
Mar. 12	Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian Patients	CI

STENOCARE: How to receive TO1 Warrant Compensation

December 29, 2023 at 06:12 am EST

STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO

The promise: On November 29, 2023, STENOCARE announced the decision to amend the terms relating to the now completed exercise of TO1 Warrants. As part of this, the set minimum (and maximum) price for exercise of the TO1 warrant was removed. This was done to honor the promises of a 30% discount to all TO1 subscribers made at the time of the rights issue in June 2023.

The Compensation Offer: The announcement on November 29, 2023 also included an offer for compensation for TO1 Warrant owners that would realise a loss due to the amended terms. Stenocare announced compensation details on December 6. The offer is for TO1 Warrants owners that 1) sold TO1 warrants before November 29, then 2) repurchased warrants at a loss after November 29 and 3) also exercised these warrants before December 19, 2023. In summary:

Condition #1: The warrant holder must have sold warrants of TO1 between 20 June 2023, 9.00 AM (CEST) and 29 November 2023, 4.41 PM (CET)
Condition #2: The warrant holder must have purchased TO1 warrants between 29 November 2023, 4.42 PM (CET) and 15 December 2023, 5.00 PM (CET)
Condition #3: Compensation is given if the warrant holder has realized a loss (ie. purchase price minus sales price)
Condition #4: The warrant holder must have exercised the number of warrants of series TO1 between 6 December 2023, 9.00 AM (CET) and 19 December 2023, 5.00 PM (CET) that is being requested for compensation.
Detailed terms apply and full bank documentation for related transactions is required. See link below.

The procedure: The TO1 Warrant exercise period has ended, and Stenocare shareholders who fulfill the requirements for the TO1 Warrant compensation ref. above must download, fill in, sign and submit the "Compensation Request Form" from https://stenocare.com/compensation/ on the Stenocare investor page no later than January 12, 2024. Stenocare will process eligible shareholders requests and transfer compensation payments by end of January 2024.

For additional information regarding STENOCARE, please contact:
Thomas Skovlund Schnegelsberg, CEO Phone: +45 31770060 E-mail: presse@stenocare.com

STENOCARE's Certified Adviser is Keswick Global AG / Phone: +43 1 740 408045 / E-mail: info@keswickglobal.com

About STENOCARE A/S
Stenocare was founded in 2017 with the purpose of supplying prescription-based medical cannabis to patients in Denmark and internationally. The company was first to receive the Danish Medicines Agency's permission to import, distribute as well as cultivate and produce medical cannabis. Stenocare sources its products from a number of carefully selected international high-quality suppliers and operates a unique, indoor state-of-the-art cultivation facility in Denmark, that has multiple levels of redundancy to safeguard quality and uniformity in a pesticide free production process.
www.stenocare.com www.stenocare.dk

https://news.cision.com/stenocare/r/stenocare--how-to-receive-to1-warrant-compensation,c3902436

https://mb.cision.com/Main/17551/3902436/2517382.pdf

Latest news about Stenocare A/S

Stenocare A/S Announces That the New STENOCARETHC/CBD Medical Cannabis Oil Product Available for Sale in Denmark	Apr. 18	CI
Stenocare A/S to Deliver New Medical Cannabis Oil Product for Australian Patients	Mar. 12	CI
Stenocare Gets Nod for Sale of Medical Cannabis Oil Product in Denmark	Feb. 26	MT
STENOCARE Receives Approval to Sell a New Medical Cannabis Oil Product in Denmark	Feb. 26	CI
Stenocare A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Stenocare A/S Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Danish Medical Cannabis Group Stenocare Secures Refinancing Deal	Jan. 12	MT
Stenocare A/S Reaches Refinancing Agreement Covering All Existing Debt of DKK 8.2 Million	Jan. 12	CI
Stenocare Aims to Boost Sales in Australia via Quest Biotech Pharma Team up	Dec. 14	MT
Stenocare A/S Enters into A New Partnership Agreement with Quest Biotech Pharma	Dec. 14	CI
Stenocare A/S Expands Presence with New Medical Cannabis Oil Product	Nov. 23	CI
Stenocare A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Stenocare to Supply, Sell Medical Cannabis in Germany; Shares Surge	23-10-30	MT
Stenocare Ready to Ship Medical Cannabis to German Patients	23-10-30	CI
Stenocare A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-17	CI
Stenocare A/S Provides Sales Guidance for the Year 2023	23-08-17	CI
Stenocare A/S Provides Update on Their Strong Danish Product Pipeline	23-07-27	CI
Stenocare A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	23-06-20	CI
Stenocare Raises DKK10.7 Million from Oversubscribed Rights Offering; Falls 10%	23-06-12	MT
Denmark’s Stenocare Teams Up with International Partner for New Cannabis Oil Product	23-06-02	MT
Stenocare A/S Reports on Significant Progress in Development of Its New Innovative Medical Cannabis Product	23-06-02	CI
Stenocare A/S Launches IT-Platform for Online Clinics	23-05-30	CI
Denmark's Stenocare Wins Regulatory Nod to Enter German Market	23-05-25	MT
Stenocare A/S Expands into Germany with Local Partner, ADREX Pharma	23-05-25	CI
Stenocare A/S Auditor Raises 'Going Concern' Doubt	23-03-15	CI

Chart Stenocare A/S

Duration

Period

More charts

Company Profile

STENOCARE A/S is a Denmark-based company, which is engaged in the production of medical cannabis products to patients. The Companyâs business model has two divisions: Import and wholesale of finished medical cannabis products for Danish patients, as well as Operate own cultivation- and production facility in Denmark to produce finished cannabis products for Danish and European patients. The Company distributes its products through pharmacies and hospitals. Stenocare's head office is located in Randers, Denmark.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
STENOCARE A/S	+96.46%	12.96M
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B

Alternative Medicine

Stenocare A/S

Equities

STENO

DK0061078425

Pharmaceuticals

STENOCARE: How to receive TO1 Warrant Compensation

Latest news about Stenocare A/S

Chart Stenocare A/S

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Alternative Medicine